JP2012529508A - 腸透過性のｅｇｆｒおよびｐａｒ２調節 - Google Patents

腸透過性のｅｇｆｒおよびｐａｒ２調節 Download PDF

Info

Publication number
JP2012529508A
JP2012529508A JP2012514946A JP2012514946A JP2012529508A JP 2012529508 A JP2012529508 A JP 2012529508A JP 2012514946 A JP2012514946 A JP 2012514946A JP 2012514946 A JP2012514946 A JP 2012514946A JP 2012529508 A JP2012529508 A JP 2012529508A
Authority
JP
Japan
Prior art keywords
zonulin
prehaptoglobin
disease
cell
glycoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529508A5 (fr
Inventor
ファザーノ，アレッシオ
ラマース，カレン
シア‐ドナヒュー，テレズ
ゴールドブラム，シメオン
Original Assignee
ユニバーシティ オブ メリーランド，ボルチモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ メリーランド，ボルチモア filed Critical ユニバーシティ オブ メリーランド，ボルチモア
Publication of JP2012529508A publication Critical patent/JP2012529508A/ja
Publication of JP2012529508A5 publication Critical patent/JP2012529508A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012514946A 2009-06-10 2010-06-10 腸透過性のｅｇｆｒおよびｐａｒ２調節 Pending JP2012529508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18566209P 2009-06-10 2009-06-10
US61/185,662 2009-06-10
PCT/US2010/001670 WO2010144140A2 (fr) 2009-06-10 2010-06-10 Régulation par egfr et par2 de la perméabilité intestinales

Publications (2)

Publication Number Publication Date
JP2012529508A true JP2012529508A (ja) 2012-11-22
JP2012529508A5 JP2012529508A5 (fr) 2013-07-18

Family

ID=43309408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514946A Pending JP2012529508A (ja) 2009-06-10 2010-06-10 腸透過性のｅｇｆｒおよびｐａｒ２調節

Country Status (7)

Country Link
EP (1) EP2440246A4 (fr)
JP (1) JP2012529508A (fr)
KR (1) KR20120031496A (fr)
CN (2) CN102481362A (fr)
AU (1) AU2010259213A1 (fr)
CA (1) CA2765075A1 (fr)
WO (1) WO2010144140A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019298A1 (fr) 2020-07-22 2022-01-27 富士フイルム和光純薬株式会社 Procédé d'aide au diagnostic d'une maladie intestinale inflammatoire
JP7509361B2 (ja) 2020-07-22 2024-07-02 富士フイルム株式会社 炎症性腸疾患の診断を補助する方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107329A1 (en) * 2009-06-10 2012-05-03 University Of Maryland, Baltimore EGFR and PAR2 Regulation of Intestinal Permeability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002524393A (ja) * 1998-08-03 2002-08-06 ユニバーシテイ・オブ・メリーランド・ボルチモア ゾヌリンのペプチドアンタゴニストおよびその使用方法
JP2006524098A (ja) * 2003-04-24 2006-10-26 エム レヴィ、マーク 服用可能胃腸デバイス
JP2008545951A (ja) * 2005-05-13 2008-12-18 ユニバーシティ オブ メリーランド， ボルチモア ゾヌリンを決定することによる、処置養生法の有効性を評価するための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
WO2005116236A2 (fr) * 2004-05-14 2005-12-08 The Regents Of The University Of California Methodes de traitement du cancer au moyen d'anticorps monoclonaux anti-wnt2 et d'arn interferent court

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002524393A (ja) * 1998-08-03 2002-08-06 ユニバーシテイ・オブ・メリーランド・ボルチモア ゾヌリンのペプチドアンタゴニストおよびその使用方法
JP2006524098A (ja) * 2003-04-24 2006-10-26 エム レヴィ、マーク 服用可能胃腸デバイス
JP2008545951A (ja) * 2005-05-13 2008-12-18 ユニバーシティ オブ メリーランド， ボルチモア ゾヌリンを決定することによる、処置養生法の有効性を評価するための方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019298A1 (fr) 2020-07-22 2022-01-27 富士フイルム和光純薬株式会社 Procédé d'aide au diagnostic d'une maladie intestinale inflammatoire
JP7509361B2 (ja) 2020-07-22 2024-07-02 富士フイルム株式会社 炎症性腸疾患の診断を補助する方法

Also Published As

Publication number Publication date
CN104940927A (zh) 2015-09-30
CN102481362A (zh) 2012-05-30
KR20120031496A (ko) 2012-04-03
WO2010144140A2 (fr) 2010-12-16
CA2765075A1 (fr) 2010-12-16
AU2010259213A1 (en) 2012-01-19
EP2440246A4 (fr) 2013-08-28
WO2010144140A3 (fr) 2011-05-19
WO2010144140A4 (fr) 2011-07-14
WO2010144140A8 (fr) 2012-01-26
EP2440246A2 (fr) 2012-04-18

Similar Documents

Publication Publication Date Title
Marchesan et al. Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics
Lu et al. Imbalance of autophagy and apoptosis in intestinal epithelium lacking the vitamin D receptor
US20140363818A1 (en) EGFR and PAR2 Regulation of Intestinal Permeability
AU2021202603B2 (en) Novel therapy
Chaiyarit et al. Trefoil factors in saliva and gingival tissues of patients with chronic periodontitis
WO2008072781A1 (fr) Procédé de prévention ou de traitement d'un trouble de la mémoire chez un mammifère
Abe et al. OmpA‐like protein influences cell shape and adhesive activity of Tannerella forsythia
JP2012529508A (ja) 腸透過性のｅｇｆｒおよびｐａｒ２調節
US10829563B2 (en) Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
Park et al. Granulocyte colony-stimulating factor reduces the endoplasmic reticulum stress in a rat model of diabetic cardiomyopathy
CA3038048A1 (fr) Compositions de restauration de l'expression des genes dans les troubles neuropsychiatriques ou neurodegeneratifs
Ludvigsen et al. Identification and characterization of novel ERC‐55 interacting proteins: Evidence for the existence of several ERC‐55 splicing variants; including the cytosolic ERC‐55‐C
EP2415876B1 (fr) Procédé de détection hautement sensible pour des bactéries de cavité buccale à virulence élevée
Davis Leukemia Inhibitory Factor as a Neuroprotective Agent against Focal Cerebral Ischemia
Ferrari Characterization of mouse models to study the pathogenesis of celiac disease and the role played by the dysregulation of the intestinal microbiota
Norlander SGK1, influenced by salt and IL-17A, promotes hypertension and end-organ damage
Zhang CXCL10 and Its Receptor CXCR3 Promote Non-alcoholic Steatohepatitis through Mediating Inflammatory Cytokines and Autophagy
Pizzo et al. and Tumor Necrosis Factor Receptor 1/Tumor Necrosis Factor α Behavior of Tumor Necrosis Factor
Tseng Lysosomal destabilization in retinal pigment epithelial cells activates the NLRP3 inflammasome and induces IL-1β secretion
Wünsch Colonic expression of the intestinal peptide transporter PEPT1 is not associated with inflammatory bowel diseases in humans and mouse models

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150316

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150907

A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150925